Formycon Delay Pushes Back Coherus’ Ranibizumab
FDA Requests Additional Data On Lucentis Rival
Formycon and Bioeq’s US filing for a biosimilar ranibizumab rival to Lucentis has been delayed after the FDA requested further data following a manufacturing change. Rights to the biosimilar have been licensed exclusively to Coherus in the US.
